See "Specific therapies in CLL: mechanisms of resistance and tactics for administration" on website page 471. Duvelisib was the next PI3K inhibitor permitted from the FDA, also based upon a phase III randomized trial.one hundred thirty The efficacy and security profile from the drug loo